Physician profile
Sally A Abbott
NPI 1891788626
$909.03
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143 · 2020: $114 · 2021: $290 · 2022: $362.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $169.91 | 2021-2022 | |
| Abbvie INC. | $149.04 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.43 | 2019-2021 | |
| Genzyme Corporation | $108.90 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $94.46 | 2022 | |
| Vifor Pharma, INC. | $63.54 | 2020 | |
| Intuitive Surgical, INC. | $50.00 | 2020 | |
| Janssen Pharmaceuticals, INC | $44.48 | 2019 | |
| Novartis Pharmaceuticals Corporation | $39.68 | 2019 | |
| Dysis Medical, INC. | $27.15 | 2022 | |
| Sunovion Pharmaceuticals INC. | $24.23 | 2019 | |
| Boston Scientific Corporation | $16.21 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sally Abbott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.